- Edwards Lifesciences' (NYSE:EW) Conservative Accounting Might Explain Soft Earnings
May 13, 2026
Soft earnings didn't appear to concern Edwards Lifesciences Corporation's (NYSE:EW) shareholders over the last week. We did some digging, and we believe the earnings are stronger than they seem.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NYSE:EW Earnings and Revenue History May 13th 2026
The Impact Of Unusual Items On Profit
To properly understand Edwards Lifesciences' profit results, we need to consider the US$662m expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. Assuming those unusual expenses don't come up again, we'd therefore expect Edwards Lifesciences to produce a higher profit next year, all else being equal.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On Edwards Lifesciences' Profit Performance
Because unusual items detracted from Edwards Lifesciences' earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Edwards Lifesciences' earnings potential is at least as good as it seems, and maybe even better! Unfortunately, though, its earnings per share actually fell back over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. Case in point: We've spotted 3 warning signs for Edwards Lifesciences you should be aware of.
This note has only looked at a single factor that sheds light on the nature of Edwards Lifesciences' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments
- Is EW Overvalued? DCF Says Worth $51
May 13, 2026 · gurufocus.com
On May 13, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown varied price performance recently. The stock has ex
- Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript
May 12, 2026 · seekingalpha.com
Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- Is Edwards Lifesciences Corp (EW) a Bargain After 3.5% Drop? GF Value Says Undervalued
May 11, 2026 · gurufocus.com
On May 11, 2026, Edwards Lifesciences Corp (EW) shares fell 3.5%, bringing the current price to $77.17. The stock has experienced a 52-week range of $72.30 to $
- Edwards Lifesciences (EW) is Benefitting from Expanding Its Aortic Valve Franchise
May 11, 2026
Artisan Partners, an investment management company, released its first-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. A copy of the letter is available to download here. In Q1 2026, the Artisan Mid Cap Fund reported negative absolute returns but slightly outperformed the Russell Midcap® Growth Index. The market favored lower volatility and income-oriented equities, with value outpacing growth significantly. Despite challenges for growth strategies, selective stock choices in sectors like industrials and healthcare provided strength, while consumer discretionary faced weaknesses. Mid- and small-cap indices showed resilience amid lagging large-cap growth stocks. The escalating conflict in Iran influenced market behavior, and AI-related investments continued to support capital spending and earnings. In addition, please check the Fund’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Fund highlighted stocks like Edwards Lifesciences Corporation (NYSE:EW). Edwards Lifesciences Corporation (NYSE:EW) is a leading medical technology company specializing in the treatment of advanced cardiovascular diseases. On May 8, 2026, Edwards Lifesciences Corporation (NYSE:EW) closed at $79.96 per share. One-month return of Edwards Lifesciences Corporation (NYSE:EW) was 2.36%, and its shares gained 6.90% over the past 52 weeks. Edwards Lifesciences Corporation (NYSE:EW) has a market capitalization of $46.04 billion.
Artisan Mid Cap Fund stated the following regarding Edwards Lifesciences Corporation (NYSE:EW) in its Q1 2026 investor letter:
"We also added to Edwards Lifesciences Corporation (NYSE:EW), Waters and Arthur J. Gallagher during the quarter. Edwards Lifesciences designs, develops, manufactures and markets products and services for the treatment of late-stage cardiovascular disease. The company has a long history of leadership in heart valve replacement products and is the market leader in minimally invasive valves delivered via catheters. We added to the position as the core aortic valve franchise has been reaccelerating and demand for newer tricuspid valves has been rapidly growing, expanding Edwards’ addressable market. This next product cycle is supported by strong clinical data and increasing physician adoption, with Edwards gaining share as competing solutions have struggled to match its clinical outcomes. After several years of heavy investment to support long-term growth, we expect stronger revenue growth to drive margin expansion."
Story Continues
Jim Cramer Notes Edwards Lifesciences (EW) is in a “Good Zone”
Edwards Lifesciences Corporation (NYSE:EW) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 64 hedge fund portfolios held Edwards Lifesciences Corporation (NYSE:EW) at the end of the fourth quarter, the same as in the previous quarter. While we acknowledge the potential of Edwards Lifesciences Corporation (NYSE:EW) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
In another article, we covered Edwards Lifesciences Corporation (NYSE:EW) and shared the list of best medical device stocks to invest in. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
View Comments
- AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth
May 10, 2026 · youtube.com
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), advances in diagnostics from Natera (NTRA), and continued strength in med tech leaders like Intuitive Surgical (ISRG) and Edwards Lifesciences (EW) as key areas of expansion.
- Edwards names Theodora Mistras as CFO
May 5, 2026
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter.
Name: Theodora “Doretta” Mistras
New title: CFO, Edwards Lifesciences
Previous title: CFO, Viatris
Edwards Lifesciences has chosen Theodora “Doretta” Mistras as its next CFO.
Mistras’ appointment is effective at the end of May, the company said on Monday. She replaces Scott Ullem, whose decision to step down from the job after about 12 years was announced in October. Ullem will continue as a strategic adviser to Edwards.
Mistras has been CFO at pharmaceutical firm Viatris since March 2024, overseeing financial planning, reporting and operational finance for the global organization.
Before joining Viatris, she was a managing director in healthcare investment banking at Citigroup Global Markets and held senior leadership positions in healthcare investment banking at Goldman Sachs. Her experience includes helping guide boards and executive teams on corporate finance, strategy and investor relations.
Mistras’ time as CFO of a large public healthcare company and her familiarity with the investing side should make her a good fit for the new role, said BTIG analyst Marie Thibault. In April, Edwards raised its 2026 sales growth outlook, buoyed by strength in its transcatheter aortic replacement valve business in the first quarter. “Given the planned nature of this CFO transition, we are not expecting major changes to [Edwards’] financial outlook,” Thibault wrote in a research note.
Citi Research analyst Joanne Wuensch expected the appointment to be welcomed on Wall Street, writing that the announcement should be viewed positively by investors “now that the overhang on the CFO position has been addressed.”
Recommended Reading
Edwards raises 2026 forecast as TAVR sales surge
View Comments
- Edwards Lifesciences Announces Appointment of CFO
May 4, 2026
IRVINE, Calif., May 04, 2026--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora ("Doretta") Mistras as the company’s corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role.
Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company’s global finance organization and overseeing financial planning, reporting and operational finance across a complex, global business. Prior to Viatris, she was a managing director in healthcare investment banking at Citigroup Global Markets, and earlier in her career held senior leadership roles in healthcare investment banking at Goldman Sachs. Mistras brings decades of healthcare leadership experience helping guide corporate boards and executive teams on corporate finance, strategy and investor relations. She holds a bachelor’s degree in international studies from the University of Pennsylvania and a bachelor’s degree in economics from the Wharton School.
"We are very pleased to welcome Doretta to Edwards as our next CFO," said Bernard Zovighian, Edwards’ CEO. "Doretta’s broad experience will be instrumental as we execute our differentiated strategy. We look forward to her leadership as we continue to invest in innovation, and also deliver distinguished and durable financial results and long-term value to patients, customers, shareholders and the broader healthcare ecosystem."
Ullem has served as Edwards’ CFO since 2014. "We would like to once again thank Scott for his outstanding leadership, partnership and impact," Zovighian added. "His commitment to a thoughtful transition and his continued support as a strategic advisor in the months ahead reflects the discipline and continuity that have long defined Edwards’ approach to leadership. We are grateful for Scott’s numerous contributions over the years that have helped to strengthen our company both strategically and financially."
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
Story Continues
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements made by Mr. Zovighian regarding Mistras’ experience being instrumental to the Edwards strategy to deliver long-term value to our stakeholders, the commencement of Mistras’ appointment in May 2026 and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260504913321/en/
Contacts
Media: Amy Meshulam, media@edwards.com
Investors: Gerianne Sarte, investor_relations@edwards.com
View Comments
- Edwards Lifesciences Announces Appointment of CFO
May 4, 2026 · businesswire.com
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora (“Doretta”) Mistras as the company's corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role. Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company's global finance organization and overseeing financial planni.
- EDWARDS LIFESCIENCES ANNOUNCES APPOINTMENT OF CFO
May 4, 2026
IRVINE, CALIF.--(BUSINESS WIRE)--EDWARDS LIFESCIENCES (NYSE: EW) TODAY ANNOUNCED THE APPOINTMENT OF THEODORA (“DORETTA”) MISTRAS AS THE COMPANY'S CORPORATE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER (CFO), EFFECTIVE AT THE END OF MAY. MISTRAS WILL SUCCEED SCOTT ULLEM, WHO ANNOUNCED IN OCTOBER HIS PLANNED TRANSITION FROM THE CFO ROLE. MISTRAS JOINS EDWARDS FROM VIATRIS, WHERE SHE HAS SERVED AS CFO SINCE MARCH 2024, LEADING THE COMPANY'S GLOBAL FINANCE ORGANIZATION AND OVERSEEING FINANCIAL PLANNI.
